NDC product
Ipratropium Bromide Inhalation
NDC 17270-0401 · Armstrong Pharmaceuticals, Inc.
Key facts
| Product NDC | 17270-0401 |
|---|---|
| Proprietary name | Ipratropium Bromide Inhalation |
| Nonproprietary name | Ipratropium Bromide Inhalation |
| Substances | IPRATROPIUM BROMIDE |
| Dosage form | AEROSOL |
| Route | RESPIRATORY (INHALATION) |
| Labeler | Armstrong Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA217953 |
| Pharmacologic classes | Anticholinergic [EPC], Cholinergic Antagonists [MoA] |
| Marketing start | Apr 16, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: